Adaptive Biotechnologies

Some of the biggest players in the life science tools and diagnostics industries including Danaher, Agilent, and Hologic presented on day two of the conference, discussing plans for 2018.

The companies are planning to develop individual disease diagnostics, and then a universal diagnostic from a single blood test.

Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.

Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials. 

The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.

The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology. 

Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.

Adaptive aims to commercialize and scale its techniques to identify immune signatures in other infectious diseases, autoimmune disorders, and even cancer.

The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL. 

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.